Market Place
Sourcing Support
Medmira Reports First Quarter Results FY2026
30 Dec 2025 //
ACCESSWIRE
Health Canada Approves MedMira`s Reveal(R) Rapid TP Test
26 Aug 2025 //
PHARMAWEB
MedMira launches clinical trial for Multiplo(R) TP/HIV self-test
07 Jul 2025 //
ACCESSWIRE
MedMira Reports Second Quarter Results FY2025
30 Jun 2025 //
ACCESSWIRE
MedMira Reports Second Quarter Results FY2025
01 Apr 2025 //
ACCESSWIRE
MedMira Partners With MediGroup For US Physician Services Expansion
27 Feb 2025 //
ACCESSWIRE
MedMira Announces Distribution Agreement with Trimedic for Canada
25 Feb 2025 //
ACCESSWIRE
MedMira’s Reveal G4 HIV Test Gains Health Canada Approval
14 Jan 2025 //
ACCESSWIRE
MedMira Gets Testing Authorization for Multiplo(R) Syphilis Test
09 Jan 2025 //
ACCESSWIRE
MedMira Reports First Quarter Results FY2025
30 Dec 2024 //
ACCESSWIRE
MedMira Receives Health Canada Approval for Multiplo Rapid Test
24 Dec 2024 //
ACCESSWIRE
MedMira Reports FY2024 Q4 & Year-End Financial Results
28 Nov 2024 //
ACCESSWIRE
MedMira Announces Appoints VP Of Commercial Operations
03 Oct 2024 //
ACCESSWIRE
MedMira Reports Third Quarter Results FY2024
02 Jul 2024 //
ACCESSWIRE
MedMira Announces the Hire of Vice President of Business Development
30 Apr 2024 //
ACCESSWIRE
MedMira Reports Second Quarter Results FY2024
01 Apr 2024 //
ACCESSWIRE
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
13 Mar 2024 //
ACCESSWIRE
Corporate Update on Clinical Evaluation of MedMira’s Products
01 Feb 2024 //
ACCESSWIRE
MedMira Reports First Quarter Results FY2024
29 Dec 2023 //
ACCESSWIRE
U.S. FDA Approves MedMira`s Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
13 Dec 2023 //
ACCESSWIRE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
28 Nov 2023 //
ACCESSWIRE
MedMira Reports Second Quarter Results FY2023
03 Apr 2023 //
ACCESSWIRE
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
14 Mar 2023 //
ACCESSWIRE
MedMira Enters into Partnership with Maternova for USA and Latin America
20 Feb 2023 //
ACCESSWIRE
Point-ofCare Diagnostic for Trichomonas Vaginalis Based MedMira`s RVF Technology
03 Jan 2023 //
ACCESSWIRE
MedMira Introduces VYRA TriDemic
29 Dec 2022 //
ACCESSWIRE
MedMira Strengthens and Expands Board
14 Jul 2022 //
GLOBENEWSWIRE
MedMira Reports Third Quarter Results FY2022
29 Jun 2022 //
GLOBENEWSWIRE
MedMira Receives Patent for its Unique Quantitative Diagnostic System
06 Jun 2022 //
GLOBENEWSWIRE
MedMira provides an update on the new IVDR in the European Market
27 May 2022 //
GLOBENEWSWIRE
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
12 May 2022 //
GLOBENEWSWIRE
MedMira receives the CE mark for Reveal TP (Syphilis) and starts trials
09 Mar 2022 //
GLOBENEWSWIRE
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
08 Feb 2022 //
GLOBENEWSWIRE
MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities
21 Dec 2021 //
GLOBENEWSWIRE
MedMira Closes New Equity Investment for Future Growth
15 Jul 2021 //
GLOBE NEWSWIRE
MedMira Closes New Equity Investment for Future Growth
14 Jul 2021 //
GLOBENEWSWIRE
